Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Dubrovskiy
In Vitro and in Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Molecular Cancer Therapeutics
Cancer Research
Oncology
X-Band Rf Power Production and Deceleration in the Two-Beam Test Stand of the Compact Linear Collider Test Facility
Physical Review Special Topics - Accelerators and Beams
Related publications
Structural Differences Between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors
Journal of the American Chemical Society
Biochemistry
Colloid
Catalysis
Chemistry
Surface Chemistry
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Clinical Cancer Research
Cancer Research
Oncology
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression
Molecular Cancer Therapeutics
Cancer Research
Oncology
Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Cancer Research
Cancer Research
Oncology
New Heteroaryl Carbamates: Synthesis and Biological Screening in Vitro and in Mammalian Cells of Wild-Type and Mutant HIV-protease Inhibitors
Bioorganic and Medicinal Chemistry
Organic Chemistry
Molecular Medicine
Molecular Biology
Biochemistry
Clinical Biochemistry
Pharmaceutical Science
Drug Discovery
Selective Inhibitors of the Osteoblast Proteasome Stimulate Bone Formation in Vivo and in Vitro
Journal of Clinical Investigation
Medicine
Biochemical Characterization of Arabidopsis Wild-Type and Mutant Phytochrome B Holoproteins
Plant Cell
Plant Science
Cell Biology
YH25448, an Irreversible EGFR-TKI With Potent Intracranial Activity in EGFR Mutant Non-Small-Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Structure-Based Design of 5Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)